Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.
For more information on how to use this blog and search the HCV drug pipeline click here; for more information on HCV clinical trials click here
Monday, April 30, 2012
Brivanib did not improve overall liver cancer survival, but did show anti-tumour activity
Over years or decades chronic hepatitis B or C infection – as well as heavy alcohol consumption, hereditary liver diseases and other causes – can lead to advanced liver damage including cirrhosis and hepatocellular carcinoma (HCC), a type of liver cancer.